Literature DB >> 25034355

Comparison osteopontin vs AFP for the diagnosis of HCC: a meta-analysis.

Hao-Guang Wan1, Hao Xu1, Yu-Ming Gu1, Hui Wang2, Wei Xu3, Mao-Heng Zu1.   

Abstract

BACKGROUNDS: Osteopontin (OPN) has been reported as one of the most promising markers for hepatocellular carcinoma (HCC). The goal of this meta-analysis was to evaluate the clinical value of the plasma OPN versus alpha-fetoprotein (AFP) in the diagnosis of HCC.
METHODS: A comprehensive literature search of PubMed, Foreign Medical Journal Service, Chinese Science Journals Database, and Google Scholar was conducted on articles published before 1st October 2013. The sensitivity, specificity, and other measures of accuracy of OPN in the diagnosis of HCC were pooled using random effects models. The methodological quality of each study was assessed by QUADAS (quality assessment for studies of diagnostic accuracy). Statistical analysis was performed by employing Meta-Disc 1.4 and Stata, version 12. Summary receiver operating characteristic curves were used to summarize overall test performance.
RESULTS: Seven studies were included in our meta-analysis. The summary estimates for OPN and AFP in the diagnosis of HCC in these studies as follows: sensitivity, 0.86 (0.79-0.91) vs 0.66 (0.53-0.76), specificity, 0.86 (0.69-0.94) vs 0.95 (0.87-0.98), positive likelihood ratio (PLR), 6.10 (2.43-15.32) vs 13.25 (4.69-37.49), negative likelihood ratio (NLR), 0.16 (0.09-0.28) vs 0.36 (0.26-0.51), diagnostic odds ratio (DOR), 38.52 (8.99-165.08) vs 36.75 (11.04-122.32), and the area under the curve (AUC), 0.92 vs 0.87.
CONCLUSION: Our study demonstrates that OPN has a comparable accuracy to AFP for the diagnosis of HCC, while the value of OPN in combination with AFP for HCC detection deserves further investigation.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25034355     DOI: 10.1016/j.clinre.2014.06.008

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  26 in total

1.  Downregulation of RIP140 in hepatocellular carcinoma promoted the growth and migration of the cancer cells.

Authors:  Dexiang Zhang; Yueqi Wang; Yuedi Dai; Jiwen Wang; Tao Suo; Hongtao Pan; Han Liu; Sheng Shen; Houbao Liu
Journal:  Tumour Biol       Date:  2014-11-13

Review 2.  Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis.

Authors:  Kerstin Schütte; Christian Schulz; Alexander Link; Peter Malfertheiner
Journal:  World J Hepatol       Date:  2015-02-27

Review 3.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 4.  Biomarker development for hepatocellular carcinoma early detection: current and future perspectives.

Authors:  Shreya Sengupta; Neehar D Parikh
Journal:  Hepat Oncol       Date:  2017-11-17

Review 5.  Role of biomarkers in the prediction and diagnosis of hepatocellular carcinoma.

Authors:  Mahmoud Khattab; Magdy Fouad; Elham Ahmed
Journal:  World J Hepatol       Date:  2015-10-18

6.  Prognostic significance of osteopontin in acute myeloid leukemia: A meta-analysis.

Authors:  Yong-Bing Chen; Si-Mei Ren; Si-Dan Li; Zhongli Du
Journal:  Mol Clin Oncol       Date:  2017-06-28

Review 7.  Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C.

Authors:  Andrea Martini; Andrea Gallotta; Patrizia Pontisso; Giorgio Fassina
Journal:  World J Hepatol       Date:  2015-12-18

Review 8.  Diagnostic and therapeutic management of hepatocellular carcinoma.

Authors:  Francesco Bellissimo; Marilia Rita Pinzone; Bruno Cacopardo; Giuseppe Nunnari
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

9.  Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging?

Authors:  Maria E Lozada; Roongruedee Chaiteerakij; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2015-06

Review 10.  Biomarkers for the early diagnosis of hepatocellular carcinoma.

Authors:  Nobuhiro Tsuchiya; Yu Sawada; Itaru Endo; Keigo Saito; Yasushi Uemura; Tetsuya Nakatsura
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.